Short Treatment with Omalizumab for Severe Asthma

PHASE4RecruitingINTERVENTIONAL
Enrollment

234

Participants

Timeline

Start Date

May 20, 2021

Primary Completion Date

May 20, 2027

Study Completion Date

May 20, 2027

Conditions
Asthma
Interventions
OTHER

Attempt to withdrawal OMA treatment

Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line

DRUG

Continuation of OMA treatment

"Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels.~In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care."

Trial Locations (1)

75018

RECRUITING

Hôpital Bichat-Claude Bernard, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER